TG Sino-Dragon Fund

TG Sino-Dragon Fund operates as a venture capital and private equity investment firm, specializing in the biotech and life sciences sectors. The fund strategically deploys capital into emerging companies, aiming to foster innovation and advance therapeutic solutions. It focuses on identifying and supporting firms with promising technologies and development pipelines within the healthcare industry.

Established in 2019, TG Sino-Dragon Fund emerged from a collaboration between Temasek Holdings and Hangzhou Tigermed Consulting Company. The fund was conceived to leverage Tigermed's deep domain expertise in clinical research with Temasek's extensive global investment acumen. This partnership aimed to capitalize on growth opportunities within the rapidly evolving biotechnology landscape.

The fund's primary focus is on innovative biotech companies seeking capital and strategic guidance to bring their medical advancements to fruition. TG Sino-Dragon Fund’s vision centers on accelerating the development of novel treatments and healthcare solutions. By investing in these enterprises, it seeks to contribute to the global health ecosystem, supporting the creation of therapies that address significant unmet medical needs.